Victoria Creamer Sells 4,179 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Victoria Creamer sold 4,179 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president owned 30,051 shares in the company, valued at $7,788,017.16. This represents a 12.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Charles River Laboratories International Price Performance

CRL opened at $281.70 on Wednesday. The company has a fifty day moving average price of $218.88 and a two-hundred day moving average price of $189.84. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $282.39. The firm has a market capitalization of $13.45 billion, a PE ratio of -58.08, a P/E/G ratio of 2.87 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same quarter in the prior year, the business posted $3.12 EPS. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 11.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cardinal Capital Management boosted its stake in Charles River Laboratories International by 0.6% in the fourth quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock valued at $2,180,000 after buying an additional 62 shares in the last quarter. Asset Management One Co. Ltd. grew its position in Charles River Laboratories International by 4.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock valued at $375,000 after acquiring an additional 71 shares during the last quarter. Glenmede Trust Co. NA raised its stake in Charles River Laboratories International by 2.8% during the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock worth $467,000 after acquiring an additional 73 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Charles River Laboratories International by 1.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock worth $1,260,000 after acquiring an additional 80 shares during the last quarter. Finally, Advisory Services Network LLC lifted its holdings in shares of Charles River Laboratories International by 2.6% in the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after acquiring an additional 83 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Analyst support remains favorable. Piper Sandler set a $300 price target, while Barclays maintained an overweight rating and a $300 target. RBC also raised its target to $282 and reiterated an outperform rating. Overall, 12 analysts rate CRL a Buy, three recommend Hold and one recommends Sell, producing a consensus “Moderate Buy” rating. Charles River Laboratories International Given Consensus Rating of Moderate Buy
• Positive Sentiment: Recent operating results exceeded expectations. Charles River reported quarterly adjusted earnings of $3.02 per share versus the $2.77 consensus estimate, while revenue of approximately $1.0 billion topped expectations of $980.5 million. Fiscal 2026 earnings guidance remains $11.15 to $11.45 per share.
• Positive Sentiment: Strong momentum has attracted attention. CRL reached a new 52-week high near $277, with trading volume above its average. The stock is also well above its 50-day and 200-day moving averages, indicating continued technical momentum. Charles River Laboratories International Sets New 52-Week High
• Neutral Sentiment: International-market exposure remains an investor focus. A recent analysis examines how Charles River’s international revenue trends could affect Wall Street forecasts and the stock’s outlook, but the provided report does not identify a specific estimate change. International Markets and Charles River Deep Dive
• Negative Sentiment: Several insiders sold shares. Director James C. Foster sold 28,733 shares for approximately $7.9 million under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 47.6%. EVP Victoria Creamer sold 4,179 shares worth about $1.1 million, and CAO Michael Gunnar Knell sold 6,645 shares worth approximately $1.7 million. These planned transactions may raise caution, although they do not necessarily signal deteriorating business prospects. SEC insider transaction filing

Analyst Upgrades and Downgrades

CRL has been the topic of a number of recent analyst reports. Robert W. Baird set a $291.00 target price on Charles River Laboratories International in a report on Thursday, August 6th. Citigroup reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Morgan Stanley increased their price target on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research report on Friday. TD Cowen boosted their price objective on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a report on Monday. Finally, Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $255.65.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.